GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » E10

BriaCell Therapeutics (FRA:8BT0) E10 : €-88.33 (As of Jan. 2025)


View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Jan. 2025 was €-2.251. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-88.33 for the trailing ten years ended in Jan. 2025.

During the past 3 years, the average E10 Growth Rate was 30.10% per year. During the past 5 years, the average E10 Growth Rate was 18.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of BriaCell Therapeutics was 30.10% per year. The lowest was 1.50% per year. And the median was 8.55% per year.

As of today (2025-03-23), BriaCell Therapeutics's current stock price is €3.99. BriaCell Therapeutics's E10 for the quarter that ended in Jan. 2025 was €-88.33. BriaCell Therapeutics's Shiller PE Ratio of today is .


BriaCell Therapeutics E10 Historical Data

The historical data trend for BriaCell Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics E10 Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -307.46 -279.81 -301.74 -265.40 -88.52

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -284.23 -265.43 -88.52 -87.04 -88.33

Competitive Comparison of BriaCell Therapeutics's E10

For the Biotechnology subindustry, BriaCell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Shiller PE Ratio falls into.



BriaCell Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Jan. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=-2.251/127.4427*127.4427
=-2.251

Current CPI (Jan. 2025) = 127.4427.

BriaCell Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201504 -34.584 99.710 -44.203
201507 -21.141 100.579 -26.787
201510 -30.668 100.500 -38.890
201601 -29.654 100.184 -37.722
201604 -31.583 101.370 -39.706
201607 -27.395 101.844 -34.281
201610 -30.460 102.002 -38.057
201701 -32.282 102.318 -40.209
201704 -61.542 103.029 -76.125
201707 -122.514 103.029 -151.545
201710 -29.853 103.424 -36.786
201801 -29.913 104.056 -36.636
201804 -28.556 105.320 -34.554
201807 89.583 106.110 107.593
201810 -19.204 105.952 -23.099
201901 -29.116 105.557 -35.153
201904 -25.750 107.453 -30.540
201907 -35.334 108.243 -41.601
201910 -24.819 107.927 -29.307
202001 -26.693 108.085 -31.474
202004 -9.652 107.216 -11.473
202007 -17.403 108.401 -20.460
202010 -6.885 108.638 -8.077
202101 -3.694 109.192 -4.311
202104 7.900 110.851 9.082
202107 -13.387 112.431 -15.174
202110 -23.403 113.695 -26.233
202201 9.415 114.801 10.452
202204 -9.029 118.357 -9.722
202207 -0.442 120.964 -0.466
202210 -1.066 121.517 -1.118
202301 -10.718 121.596 -11.233
202304 -4.378 123.571 -4.515
202307 -2.034 124.914 -2.075
202310 -7.102 125.310 -7.223
202401 -9.768 125.072 -9.953
202404 1.538 126.890 1.545
202407 -0.968 128.075 -0.963
202410 -3.029 127.838 -3.020
202501 -2.251 127.443 -2.251

Add all the adjusted EPS together and divide 10 will get our e10.


BriaCell Therapeutics  (FRA:8BT0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BriaCell Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines